Premium
Abiraterone acetate: a new oral treatment for prostate cancer
Author(s) -
Chaplin Steve,
Clarke Noel
Publication year - 2012
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.940
Subject(s) - abiraterone acetate , medicine , prostate cancer , abiraterone , adverse effect , oncology , cancer , pharmacology , androgen deprivation therapy , androgen receptor
Abstract Abiraterone acetate (Zytiga) is a new treatment for metastatic castration‐resistant prostate cancer. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Noel Clarke discusses its place in therapy.